Effect of trajectories of glycemic control on mortality in type 2 diabetes: A semiparametric joint modeling approach

American Journal of Epidemiology

Volumn 171, Issue 10, 2010, Pages 1090-1098

  Gebregziabher, Mulugeta ^a,c   Egede, Leonard E ^a,b,c   Lynch, Cheryl P ^a,b,c   Echols, Carrae ^a   Zhao, Yumin ^b,c  

^a RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cohort studies; Diabetes mellitus; Glycosylated; Hemoglobin A; Mortality; Retrospective studies; Type 2; Veterans

Indexed keywords

HEMOGLOBIN A1C;

CARBOHYDRATE; COHORT ANALYSIS; CONFIDENCE INTERVAL; DATA SET; DIABETES; HEMOGLOBIN; MORTALITY; NUMERICAL MODEL;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HAZARD RATIO; HEMOGLOBIN BLOOD LEVEL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; RISK FACTOR; VETERAN;

AGED; ALGORITHMS; COHORT STUDIES; CONFIDENCE INTERVALS; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SOUTH CAROLINA; TIME FACTORS; VETERANS;

EID: 77952326968     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq070     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States 2007. Atlanta, GA: Centers for Disease Control and Prevention; 2008.
2. Moss SE, Klein R, Klein BE, et al. The association of glyce-mia and cause-specific mortality in a diabetic population. Arch Intern Med. 1994;154(21):2473-2479.
3. Andersson DK, Svärdsudd K. Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care. 1995; 18(12):1534-1543.
4. Wei M, Gaskill SP, Haffner SM, et al. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care. 1998;21(7): 1167-1172.
5. de Vegt F, Dekker JM, Ruhé HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia. 1999; 42(8):926-931.
6. Gregg EW, Gu Q, Cheng YJ, et al. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med. 2007; 147(3):149-155.
7. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281(14):1291-1297.
8. Stratton IM, Adler AI, Neil HA, et al. Association of glycae-mia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.
9. Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Ann Intern Med. 2004;141(6):413-420.
10. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ. 2001;322(7277):15-18.
11. Maynard C, Chapko MK. Data resources in the Department of Veterans Affairs. Diabetes Care. 2004;27(suppl 2): B22-B26. (Pubitemid 38569260)
12. Miller DR, Safford MM, Pogach LM. Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. Diabetes Care. 2004;27(suppl 2):B10-B21.
13. American Diabetes Association. Executive summary: standards of medical care in diabetes\2009. Diabetes Care. 2009; 32(suppl 1):S6-S12.
14. Goldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care. 2003;26(suppl 1):S106-S108.
15. Diggle PJ, Heagerty P, Liang K-Y, et al. Analysis of Longitudinal Data. 2nd ed. Oxford, United Kingdom: Oxford University Press; 2002.
16. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York, NY: Springer-Verlag; 2000.
17. Ibrahim JG, Molenberghs G. Missing data methods in longitudinal studies: a review. TEST. 2009;18(1):1-43.
18. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol. 1997;145(1):73-80.
19. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139.
20. Ye W, Lin X, Taylor JM. Semiparametric modeling of longitudinal measurements and time-to-event data\a two-stage regression calibration approach. Biometrics. 2008;64(4): 1238-1246.
21. Li L, Hu B, Greene T. A semiparametric joint model for longitudinal and survival data with application to hemodialysis study. Biometrics. 2009;65(3):737-745.
22. Guo X, Carlin BP. Separate and joint modeling longitudinal and event time data using standard computer packages. Am Stat. 2004;58(1):16-24.
23. Wang Y, Taylor JMG. Jointly modeling longitudinal and event time data with application to acquired immunodeficiency syndrome. J Am Stat Assoc. 2001;96(455):895-905.
24. Taylor JM, Yu M, Sandler HM. Individualized predictions of disease progression following radiation therapy for prostate cancer. J Clin Oncol. 2005;23(4):816-825.
25. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73(1):13-22.
26. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Hoboken, NJ: John Wiley & Sons, Inc; 2002.
27. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multi-variate incomplete failure time data by modeling marginal distribution. J Am Stat Assoc. 1989;84(408):1065-1073.
28. Diggle PJ, Sousa I, Chetwynd AG. Joint modelling of repeated measurements and time-to-event outcomes: the fourth Armit-age lecture. Stat Med. 2008;27(16):2981-2998.
29. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
30. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
31. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
32. Bo S, Ciccone G, Gancia R, et al. Mortality within the first 10 years of the disease in type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2006;16(1):8-12.
33. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836-1841.
34. Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care. 2002;25(6): 1015-1021.
35. Krapek K, King K, Warren SS, et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother. 2004;38(9):1357-1362.
36. Rozenfeld Y, Hunt JS, Plauschinat C, et al. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care. 2008;14(2):71-75.
37. Riedel AA, Heien H, Wogen J, et al. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy. 2007;27(8):1102-1110.
38. Jermendy G, Hungarian RECAP Group, Erdesz D, et al. Outcomes of adding second hypoglycemic drug after metfor-min monotherapy failure among type 2 diabetes in Hungary [electronic article]. Health Qual Life Outcomes. 2008;6:88.